The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

A non-invasive, high-accuracy surveillance test for bladder cancer has the potential to improve patient experience, streamline workflows, and reduce overall cost of care” — Megann Vaughn Watters, Vice ...

A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...

Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...

New research indicates that about one-quarter of patients with bladder cancer treated with radical surgery on curative intent have detectable levels of tumour cells circulating in their blood. The ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...